HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
100,166,035
Share change
+5,257,744
Total reported value
$948,654,684
Put/Call ratio
22%
Price per share
$9.47
Number of holders
156
Value change
+$16,486,246
Number of buys
88
Number of sells
63

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2016

As of 31 Mar 2016, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 156 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 100,166,035 shares. The largest 10 holders included Third Security, LLC, IRIDIAN ASSET MANAGEMENT LLC/CT, VANGUARD GROUP INC, BB BIOTECH AG, First Eagle Investment Management, LLC, FMR LLC, BlackRock Fund Advisors, STATE STREET CORP, JPMORGAN CHASE & CO, and BlackRock Institutional Trust Company, N.A.. This page lists 156 institutional shareholders reporting positions in this security for the Q1 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.